This integration allows for the seamless delivery of pharmacogenomic (PGx) risk assessments, advanced diagnostic test results, and ongoing PGx monitoring, empowering them to deliver better and more personalized resident care, allowing providers to quickly and easily identify potentially dangerous drug-gene interactions for their residents.
"We're pleased to announce our integration into PointClickCare's solution that helps to enable both access and efficient use of precision medicine solutions that benefit LTPAC providers and residents nationwide," said Bryon Cipriani, CEO, AccessDx Laboratory. "This integration with PointClickCare further highlights our combined interests in meeting the needs of providers and care organizations to help empower actionable, high-utility precision medicine efforts."
AccessDx Laboratory's integration with PointClickCare directly aligns with AccessDx Laboratory's mission to enable providers to effectively apply the practical benefits of precision insights within their care workflows, while ensuring the prescription of safer and more effective medications for entire patient populations.
In a multi-facility analysis, the PointClickCare integration allowed ten facilities to identify and address 77% of their residents who were found to be at risk for severe or moderate drug-gene interactions. This integration incorporates resident medications as they are updated in the system, helping clinicians who participate in the AccessDx Laboratory Risk Mitigation for Seniors Program to utilize real-time PGx insights as part of their overall care protocol.
"Our Marketplace Partners provide world-class technology and share our deep commitment to ensuring our customers have access to the most powerful, efficient, and effective solutions," said Mike Boesveld, Director, Marketplace Strategy, PointClickCare. "We are excited to integrate with AccessDx Laboratory to jointly help our mutual clients manage the complex challenges of long-term and post-acute care."
About AccessDx Laboratory:
AccessDx Laboratory is a CLIA-certified, CAP-accredited, and NYSDOH-approved diagnostic laboratory dedicated to providing clinical insights that help improve patient outcomes. AccessDx solutions include pharmacogenomics (PGx) testing, cancer genomic (CGX) testing, infectious disease testing, and a wide range of clinical laboratory research, development, and consultancy services. With demonstrated commitments to clinical and analytical excellence, turnaround time, and high-throughput operations and support infrastructure, millions of AccessDx Laboratory tests have been trusted by thousands of health systems, care providers, employer groups, and municipalities nationwide.
For more information please visit, www.accessdxlab.com.
